Background: The combination of inhaled corticosteroids and long-acting inhaled b 2 -adrenergic-agonists has become the standard therapy for many patients with moderate to severe persistent asthma. Whether the differences between budesonide/formoterol and fluticasone/salmeterol translate into differences in treatment outcomes in a real life setting is unknown. Objectives: This study compared the use of healthcare services between new users of budesonide/formoterol and fluticasone/salmeterol in a single inhaler between 2002 and 2004. Methods: A 12-month population-based retrospective cohort study using administrative health care databases was conducted. Asthma patients 16e65 years of age using budesonide/formoterol were matched according to age and markers of asthma severity to patients using fluticasone/salmeterol. The rate of emergency department (ED) visits for asthma, hospitalizations for asthma, claims for oral corticosteroids, and visits to a respiratory specialist were compared between the two groups using Poisson regression models. The mean number of doses of shortacting b 2 -adrenergic-agonists (SABA) per week was compared between the two groups using a linear regression model. Results: Users of budesonide/formoterol were found to be less likely to have an ED visit for asthma (adjusted RR Z 0.72; 95% CI: 0.54e0.96), a hospitalization for asthma (adjusted RR Z 0.50; 95% CI: 0.25e0.99), a claim for oral corticosteroids (adjusted RR Z 0.83; 95% * Statement: Patients with frequent exacerbation might be treated preferentially with budesonide/formoterol since users of these medications were found to be less likely to need acute care for asthma than users of fluticasone/salmeterol in the same inhaler. CI: 0.72e0.95), and use SABA (adjusted mean difference Z À 1.1 dose per week; 95% CI: À1.7; À0.5) than patients treated with fluticasone/salmeterol. Conclusion: Our study has found that subjects initiating ICS/LABA treatment with budesonide/ formoterol had better outcomes than those initiating treatment with fluticasone/salmeterol.
Introduction
Combination therapy with inhaled corticosteroids (ICS) and long-acting inhaled b 2 -adrenergic-agonists (LABA) is recommended by the Canadian and International Asthma Management Guidelines to treat adult persistent asthma after suboptimal improvement with an ICS. 1, 2 However, combination therapy is not recommended as a first-line therapy in patients with mild to moderate persistent asthma who have never used an ICS. 3, 4 In adults with moderate to severe persistent asthma, combination therapy is more beneficial than a higher dose of ICS with respect to lung function, symptoms, and use of rescue medication. 5e7 Two products combining an ICS and a LABA in the same inhaler are available in Canada. One product combines budesonide and formoterol in a dry powder inhaler (DPI) and the other product combines fluticasone propionate and salmeterol in either a DPI or a pressurized metered dose inhaler (pMDI). In addition to differences in the inhalation devices, these two combination products have different pharmacological properties; for example, the budesonide/ formoterol combination has been shown to have a faster onset of action than the fluticasone propionate/salmeterol combination with regards to improvements in FEV 1 , which is attributable to the faster onset of formoterol over salmeterol. 8 Furthermore, fluticasone is about 25% more potent than budesonide. 9 Despite these different pharmacological properties, the two combination products were found to lead to similar benefits in terms of preventing the symptoms of asthma, use of rescue medications and lung function measures when they were compared at fixed dosing. 10 Recently, however, a reduction in the rate of hospitalization has been found with budesonide/formoterol combination compared to fluticasone propionate/salmeterol. 11, 12 It is unknown whether differences in pharmacologic properties translate into differences in patient adherence and consequently into clinical differences. In order to answer these questions, we undertook a population-based retrospective cohort study to compare the rate of use of acute care and ambulatory visits for asthma and treatment adherence between new users of budesonide/formoterol and new users of fluticasone propionate/salmeterol in a single inhaler.
Methods

Source of data
This study was based on the administrative health care databases of the Régie de l'assurance-maladie du Québec (RAMQ), the government body responsible for the management of health care services. In the Canadian province of Québec, the public drug insurance plan is managed by the RAMQ and covers approximately 43% of the population, including residents receiving social assistance, the elderly, and residents less than 65 years of age who have no access to a private drug insurance plan through their employer. From the RAMQ's Prescription Database, we obtained data on medication claims such as the date the medication was dispensed, name, dose, quantity, and dosage form of the prescribed medication, duration of the prescription, and the specialty of the prescribing physician. From the RAMQ's Medical Services Database, we obtained data on the dispensed medical services, such as the date and site of service (clinic, emergency department (ED) or hospital), the diagnosis coded with ICD-9, and the specialty of the treating physician. From the RAMQ, we also obtained socio-demographic data such as age, gender, type of drug insurance plan, area of residence, and where relevant, date of death. All these databases contain a patient unique identifier number that allows for the linkage between them.
Study design
We used a retrospective matched cohort in which each patient was followed for 12 months. Using the RAMQ's databases, we first selected a cohort of patients newly treated with either budesonide/formoterol or fluticasone propionate/salmeterol. Patients were included in the cohort if they fulfilled the following inclusion/exclusion criteria: (1) at least one claim for a combination therapy in 2002 or 2003; (2) no evidence of a claim for combination therapy for at least 1 year prior to the first claim (the date of the first claim of a combination therapy is referred to as the index date); (3) age between 16 and 65 years on the index date; (4) having had at least one diagnosis for asthma in the year prior to the index date (ICD-9: 493.0, 493.1, 493.9); (5) having had no diagnosis or claim for a respiratory disease other than asthma in the year prior to the index date; and (6) being covered by the RAMQ's Public Drug Insurance Plan for at least 1 year prior and 1 year after the index date.
Patients treated with budesonide/formoterol were then one-to-one matched to patients treated with fluticasone propionate/salmeterol based upon the following criteria: age ( 25, >25e35, >35e45, >45e55, and >55e65 years old), gender, calendar year of the index date, as well as use of inhaled corticosteroids (0, !1 claim), oral corticosteroids (0, 1, 2, !3 claims), ED visits for asthma (0, 1, !2 visits), and hospitalization for asthma (0, !1 hospitalization) in the year prior to the index date. Patients entered the cohort on the index date and were followed-up for 12 months.
Compared treatments
Patients newly treated with budesonide/formoterol were compared to patients newly treated with fluticasone propionate/salmeterol in a real life setting.
Outcomes
The following outcomes were investigated: ED visits for asthma (ICD-9: 493.0, 493.1, 493.9), hospitalizations for asthma (ICD-9: 493.0, 493.1, 493.9), claims for oral corticosteroids, doses of short-acting inhaled b 2 -agonists (SABA) per week, visits to a respiratory specialist (ICD-9: 493.0, 493.1, 493.9), ambulatory medical visits (any diagnosis), and treatment adherence to a combination therapy.
To obtain an estimate of SABA use, we developed an algorithm to obtain equivalencies between the different medications dispensed using the medication's dose, formulation, date of claims, prescription renewals as well as the period between renewals. 13 Treatment adherence was defined as the number of claims of the combination therapy in the year following the index date.
Confounding variables
In order to further adjust for differences between patients treated with budesonide/formoterol and fluticasone propionate/salmeterol, we considered the following variables as potential confounders: area of residence on the index date (rural/urban), receipt of social assistance on the index date (yes/no), dose of ICS prescribed on the index date ( 500, >500 mg per day in fluticasone propionate equivalent according to the equivalences reported in the Canadian Asthma Consensus Guidelines 1 ), combination therapy initiated by a respiratory physician (yes/no) as well as the number of doses of SABA per week ( 3, !4 doses), use of LABA (yes/no), and visits to a respiratory physician in the year prior to the index date.
Statistical analyses
Users of budesonide/formoterol were first compared to users of fluticasone propionate/salmeterol with respect to the socio-demographic characteristics of the patients at cohort entry and asthma related variables using descriptive statistics. We then compared the crude proportions of patients with an ED visit for asthma, a hospitalization for asthma, a claim for oral corticosteroids, and a visit to a respiratory specialist between users of budesonide/formoterol and fluticasone propionate/salmeterol using the Chi-squared tests. In addition, the mean number of doses of SABA per week and the mean number of ambulatory medical visits in the 12-month follow-up period were compared between budesonide/formoterol and fluticasone propionate/salmeterol users with t-tests.
In order to take into account the aforementioned potential confounders, the association between all study outcomes except the use of SABA and the type of combination therapy were analyzed using the Poisson regression models. One model including all confounding variables was first built for each outcome. A backward selection strategy was then used to find the reduced model for each outcome separately.
14 Crude and adjusted rate ratios were estimated and 95% confidence intervals (CI) were reported for adjusted rate ratios. A linear regression model was used to estimate the crude and adjusted mean differences in the number of doses of SABA per week between budesonide/formoterol and fluticasone propionate/salmeterol. A backward selection strategy was also used to find the reduced model. 95% CIs were reported for adjusted mean differences.
For patients' adherence, we used a t-test to compare the mean number of claims in the year following the index date between users of budesonide/formoterol and users of fluticasone propionate/salmeterol.
Results
We initially identified 1449 asthma patients newly treated with budesonide/formoterol and 9381 asthma patients newly treated with fluticasone/salmeterol from the RAMQ databases. After matching, 1264 patients (87.2%) using budesonide/formoterol and 1264 patients (13.5%) using fluticasone/salmeterol were kept in the study matched cohort. In Table 1 , we present the characteristics of the study patients: patients were 43 years old on average, 66% were female while a minority of them lived in a rural area and received social assistance. Patients treated with budesonide/formoterol were less likely to receive higher doses of ICS when the combination therapy was started, but more likely to have their combination therapy prescribed by a respiratory specialist than patients treated with fluticasone propionate/salmeterol. Moreover, a larger proportion of the budesonide/formoterol patients had leukotriene-receptor antagonists and a visit with a respiratory specialist in the year prior to the combination therapy.
In Table 2 , we compared the crude proportions of patients with the study outcomes in the year following the index date, between the budesonide/formoterol and fluticasone propionate/salmeterol groups. Patients treated with budesonide/ formoterol were significantly less likely to have an ED visit for asthma and to use high doses of SABA, but were more likely to have a visit with a respiratory physician than patients treated with fluticasone propionate/salmeterol. Overall, there were 80 ED visits for asthma, 12 hospitalizations for asthma, and 764 visits to a respiratory specialist in the year following the initiation of the budesonide/formoterol therapy. Corresponding figures were 111, 26 and 571 in the fluticasone proprionate/salmeterol group.
In Table 3 , we present the results of the regression analyses that provided the adjusted measures of associations between the type of combination therapy and the outcomes under study. These analyses revealed that after adjustment for confounding variables, patients treated with budesonide/formoterol were significantly less likely to have an ED visit for asthma (adjusted rate ratio (RR) Z 0.72; 95% CI: 0.54e0.96), a hospitalization for asthma (adjusted RR Z 0.50; 95% CI: 0.25e0.99), a claim for oral corticosteroids (adjusted RR Z 0.83; 95% CI: 0.72e 0.95), and to use SABA (adjusted mean difference Z À 1.1 dose per week; 95% CI: À1.7; À0.5) than patients treated with fluticasone propionate/salmeterol in the year following the initiation of the combination therapy. On the other hand, we found no significant differences between the two groups for the rate of ambulatory medical visits and visits to a respiratory physician.
In terms of treatment adherence, we found that patients treated with budesonide/formoterol and fluticasone propionate/salmeterol had 4.2 and 3.9 prescriptions on average in the year following the initiation of the combination therapy, respectively (p-value Z 0.0703). The average daily dose of ICS during the study follow-up was 388 mg in fluticasone propionate equivalent for budesonide/ formoterol and 359 mg for fluticasone/salmeterol.
Discussion
In our study, users of budesonide/formoterol in a single inhaler were less likely than users of fluticasone/salmeterol in a single inhaler to have an ED visit or a hospitalization for asthma, and they also had fewer claims for oral corticosteroids and SABA.
Two clinical studies have compared the efficacy of budesonide/formoterol and fluticasone/salmeterol in fixed dosing regimens and found similar reductions in asthma exacerbations and asthma control between groups. 10, 15 In the study by Aalbers et al., 658 adults with moderate to severe asthma were randomized to budesonide/formoterol DPI 200/6 mg, two inhalations twice daily, or fluticasone/ salmeterol DPI 250/50 mg, one inhalation twice daily, and improvements in ''well-controlled asthma week'' were similar in both groups in the first month of fixed dosing. 15 The following 6 months of the study compared adjustable maintenance dosing of budesonide/formoterol to fixed dosing of fluticasone/salmeterol. Therefore, the time period was short in comparing fixed dosing strategies between both medications. In the study by Dahl et al., 1397 adults with moderate to severe asthma were randomized to receive fluticasone/salmeterol DPI 250/50 mg, one inhalation twice daily, or budesonide/formoterol DPI 200/6 mg, two inhalations twice daily, and the overall rate of asthma exacerbations (based on peak flow measurements, oral corticosteroids use and hospital admission) was similar between the groups after 6 months of follow-up. 10 More recently, Kuna et al. has found that treatment with fixed dosing of budesonide/formoterol 200/6 mg, compared with fluticasone/salmeterol 125/25 mg, two inhalations twice daily, significantly reduced the rate of the most severe asthma exacerbations requiring hospitalization or ED treatment. 11 Furthermore, a meta-analysis combining the results of these three clinical trials 10, 11, 15 showed an overall reduction in the rate of hospitalization for asthma exacerbation, 12 which is in accordance with our study results. Reasons explaining our study results remain unclear. It is unlikely that our study results are explained by differences in the clinical efficacy of budesonide and fluticasone. Even though fluticasone and budesonide have different pharmacological properties, both agents led to similar reductions in asthma exacerbations in studies using equipotent dosage in adults with chronic asthma. 16 Formoterol and salmeterol clearly have distinct pharmacological characteristics, but in clinical studies, both agents led to similar improvements in FEV 1 , 17 morning PEF, 18e21 Table 2 Crude distribution of outcomes in the year following the initiation of the combination therapy comparing patients treated with budesonide/formoterol and fluticasone proprionate/salmeterol.
BUD/FM DPI FP/SM DPI/pMDI p-value
Number of patients n Z 1264 n Z 1264 !1 ED visit for asthma, n (%) 59 (4.7) 84 (6.6) 0.031 !1 hospitalization for asthma, n (%) 11 (0. b Rate ratio adjusted for: receipt of social assistance. c Rate ratio adjusted for: dose of ICS prescribed on the index date, combination therapy initially prescribed by a respiratory specialist, use of SABA, LABA, leukotriene-receptor antagonists, and theophyllines and visit to a respiratory specialist in the year prior to the index date.
d Rate ratio adjusted for: area of residence, dose of ICS prescribed on the index date, combination therapy initially prescribed by a respiratory specialist, use of SABA, and leukotriene-receptor antagonists and visit to a respiratory specialist in the year prior to the index date.
e Rate ratio adjusted for: area of residence, receipt of social assistance, dose of ICS prescribed on the index date, combination therapy initially prescribed by a respiratory specialist, use of SABA, LABA, and leukotriene-receptor antagonists, and visit to a respiratory specialist in the year prior to the index date.
f Mean difference adjusted for: receipt of social assistance, use of SABA and LABA in the year prior to the index date.
rescue medication use, 19 and asthma symptoms, in patients who were receiving stable dose of various inhaled corticosteroids.
19e21
A few characteristics differed between the groups of subjects compared to cohort entry. Subjects on budesonide/formoterol were more likely to visit a respiratory specialist and to have a claim for a LABA or a leukotrienereceptor antagonist prior to cohort entry. These patients' characteristics are likely associated with more severe or less controlled asthma, but these differences would influence the results towards greater benefits in the fluticasone/salmeterol group, which was not found. When looking at adherence to treatment, there were more refills in the budesonide/formoterol group (4.2) than in the fluticasone/ salmeterol group (3.9), but the difference was small and not statistically significant (0.3 inhaler over a 12 month period).
Our study has some limitations. The subjects were not randomized to one of the two study groups, but users of budesonide/formoterol were matched to users of fluticasone/salmeterol according to characteristics that could have influenced the study outcomes. Furthermore, the regression analyses were done to account for potential confounding variables. The use of asthma medications is measured with filled prescriptions and this might not reflect the exact use of the medication. This is especially true for SABA since patients might have some reserve of this rescue medication, but this phenomenon should not differ between the compared groups. Asthma diagnosis was not necessarily confirmed by spirometry in all cases. However, asthma diagnosis was physician based and we used validated codes to confirm them. 22 Finally, our cohort under represents patients with high socio-economic status who have private drug insurance. However, there is no reason to believe that the socio-economic status of patients would act as an effect modifier for the associations under study.
In conclusion, our study shows more benefits of formoterol/budesonide over salmeterol/fluticasone in real clinical practice. Further studies are needed to confirm these findings and to identify reasons that could explain the observed differences in clinical effectiveness between these two combination products. Moreover, we need to understand the reasons behind the low rate of prescription renewals in order to be able to intervene efficaciously an improve drug therapy in asthma patients.
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